| TUHURA BIOSCIENCES INC. |
| USA |
| Gesundheit |
| US8989201038 / A3EWMJ |
| PL3 (Frankfurt) / HURA (NASDAQ) |
| FRA:PL3, ETR:PL3, PL3:GR, NASDAQ:HURA |
| - |
| https://tuhurabio.com/ |
|
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, incl..
>Volltext.. |
| 108.14 Mio. EUR |
| 111.06 Mio. EUR |
| - |
| -27.83 Mio. EUR |
| -27.21 Mio. EUR |
| -0.47 EUR |
| 3.56 Mio. EUR |
| 0.88 Mio. EUR |
| -26.38 Mio. EUR |
| 0.11 |
| - |
| -10.3% |
| - |
| - |
| - |
| - |
| TUHURA |
| 05.10.26 |
|
||||
|
||||
|
||||
|
||||
|